Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2021-10-11
2023-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inadvertent Hypothermia or Hyperthermia in Pediatric Radiotherapy Practices Under Anesthesia
NCT05478850
Efficacy of Cryotherapy in Managing Chemotherapy-Induced Peripheral Neuropathy in Children With Leukemia
NCT06543264
Feasibility and Accuracy of Core Temperature Measurements Using the Esophageal Temperature Probe Inserted Through the Gastric Lumen of Supraglottic Airway Device in Pediatrics
NCT05705206
Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Temperature Monitoring
NCT02031159
Continuos Body Temperature Monitoring
NCT06447337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This research was designed to be conducted as a randomised controlled experiment study until the entire sample group identified in the Paediatric Oncology Service was reached. The algorithm of neutropenia management is used to treat children who are followed up at the paediatric oncology service, where the study will be conducted, due to febrile neutropenia. The control group will consist of children who have been treated using this algorithm (only the algorithm); whereas, the experimental group will consist of the children who will be applied to cold stream in addition to this algorithm (the algorithm + cold steam application). The body temperature values of patients in the experimental and control groups will be compared (from baseline to discharge (average 3 days)).
Cold Steam Application A nebulizer is positioned in the room, and the hose end, through which the steam is released, is supplied to the ambient air and operated in continuous mode during the cold steam application.
An Atom Sanilizer 30 ultrasonic nebulizer will be used to supply cold steam to every patient. The steam capacity of the device is 2.5 ml./min., the output power is 30 W.
The nebulizer will be used solely in the patient's room from the time the patient is admitted until his temperature is stabilised. During the private use period, the machine will not be exchanged between patients. During patient use, the device is cleaned with alcohol-based rapid surface disinfectant once a day. If another patient needs it, another device in the clinic will be utilized. The unit and the hospital already have a sufficient number of devices. After the patients' usage of the nebulizer is ended, the appliance is cleaned by using an alcohol-based rapid surface disinfectant, and the accessories are sterilized with a medium-level disinfectant in the Central Sterilization Unit.
During the practice of cold steam, if the body temperature falls within the usual range (axillary 36-37 0C, tympanic 36.5-37.7 0C), the practice will be discontinued and possible hypothermia will be avoided.
Procedures to follow in the development of hypothermia;
* ABC is evaluated.
* He is monitorised.
-If there is no pulse, Advanced Life Support begins.
* A warm ambient is provided.
* He is warmed up with a blanket.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group (Only Algorithm of Febrile Neutropenia Management)
The algorithm of febril neutropenia management is used to treat children who are followed up at the paediatric oncology service, where the study will be conducted, due to febrile neutropenia. The control group will consist of children who have been treated using this algorithm (only the Algorithm of Febrile Neutropenia Management).
Control Group (Only Algorithm of Febrile Neutropenia Management)
Common Procedure Steps
1. The child is admitted to the unit and evaluated.
2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.
3. The inclusion and exclusion criteria are evaluated.
4. The group of the child to be included in the study is determined in accordance with the randomization order.
5. The first section of the patient information and follow-up form is filled out.
6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.
Procedure Steps for Control Group:
1. Common procedure steps are followed.
2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)
The experimental group will consist of the children who will be applied to cold steam in addition to this algorithm (Algorithm of Febrile Neutropenia Management + cold steam application).
Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)
Procedure Steps for Experiment Group:
1. Common procedure steps are followed.
2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control Group (Only Algorithm of Febrile Neutropenia Management)
Common Procedure Steps
1. The child is admitted to the unit and evaluated.
2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.
3. The inclusion and exclusion criteria are evaluated.
4. The group of the child to be included in the study is determined in accordance with the randomization order.
5. The first section of the patient information and follow-up form is filled out.
6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.
Procedure Steps for Control Group:
1. Common procedure steps are followed.
2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)
Procedure Steps for Experiment Group:
1. Common procedure steps are followed.
2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who are from the age of one month to eighteen years old,
* Children treated for febrile neutropenia
* Have a stable clinical condition will be included in the study
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acibadem University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zehra Kan Onturk
Assist. Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zehra Kan Öntürk, Assist Prof
Role: PRINCIPAL_INVESTIGATOR
Acibadem University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Acıbadem Health Group Maslak Hospital
Istanbul, Maslak, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson K, Bradford N, Edwards R, Nicholson J, Lockwood L, Clark JE. Improving management of fever in neutropenic children with cancer across multiple sites. Eur J Cancer Care (Engl). 2021 May;30(3):e13413. doi: 10.1111/ecc.13413. Epub 2021 Jan 28.
Green C, Krafft H, Guyatt G, Martin D. Symptomatic fever management in children: A systematic review of national and international guidelines. PLoS One. 2021 Jun 17;16(6):e0245815. doi: 10.1371/journal.pone.0245815. eCollection 2021.
Jung TH, Rho JH, Hwang JH, Lee JH, Cha SC, Woo SC. The effect of the humidifier on sore throat and cough after thyroidectomy. Korean J Anesthesiol. 2011 Dec;61(6):470-4. doi: 10.4097/kjae.2011.61.6.470. Epub 2011 Dec 20.
Lehrnbecher T. Treatment of fever in neutropenia in pediatric oncology patients. Curr Opin Pediatr. 2019 Feb;31(1):35-40. doi: 10.1097/MOP.0000000000000708.
Paolino J, Mariani J, Lucas A, Rupon J, Weinstein H, Abrams A, Friedmann A. Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Pediatr Blood Cancer. 2019 Jul;66(7):e27679. doi: 10.1002/pbc.27679. Epub 2019 Mar 27.
Taplitz RA, Kennedy EB, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 Apr;14(4):250-255. doi: 10.1200/JOP.18.00016. Epub 2018 Mar 8. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATADEK-Clinical Trials 2021/18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.